<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ISTODAX- romidepsin 
			 </strong><br>Gloucester Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ISTODAX safely and effectively.  See full prescribing information for ISTODAX.<br><br>ISTODAX<span class="Sup">®</span> (romidepsin) for injection<br><br>For intravenous infusion only<br><br>Initial U.S. Approval:  2009</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for: </p>
<ul class="Disc"><li>Treatment of cutaneous T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (CTCL) in patients who have received at least one prior systemic therapy (<a href="#S1">1</a>).</li></ul>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><ul class="Disc">
<li>14 mg/m<span class="Sup">2</span> administered intravenously (IV) over a 4-hour period on days 1, 8 and 15 of a 28-day cycle.  Repeat cycles every 28 days provided that the patient continues to benefit from and tolerates the drug (<a href="#S2.1">2.1</a>).</li>
<li>Treatment discontinuation or interruption with or without dose reduction to 10 mg/m<span class="Sup">2</span> may be needed to manage adverse drug reactions (<a href="#S2.2">2.2</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">ISTODAX for injection, 10 mg, supplied with one Diluent vial containing 2 mL (deliverable volume) of solution (<a href="#S3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Due to the risk of QT prolongation ensure that potassium and magnesium are within the normal range before administration of ISTODAX (<a href="#S5.1">5.1</a>).</li>
<li>Treatment with ISTODAX has been associated with <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; therefore, monitor these hematological parameters during treatment with ISTODAX, modify the dose as necessary (<a href="#S5.2">5.2</a>).</li>
<li>Electrocardiographic (ECG) changes have been observed.  Consider cardiovascular monitoring precautions in patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, a history of significant cardiovascular disease, and patients taking medicinal products that lead to significant QT prolongation (<a href="#S5.3">5.3</a>).</li>
<li>Based on its mechanism of action, ISTODAX may cause fetal harm when administered to a pregnant woman.  Advise women of potential harm to the fetus (<a href="#S5.4">5.4</a>, <a href="#S8.1">8.1</a>).</li>
<li>ISTODAX binds to estrogen receptors.  Advise women of childbearing potential that ISTODAX may reduce the effectiveness of estrogen-containing contraceptives (<a href="#S5.5">5.5</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions in Study 1 were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and in Study 2 were <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, ECG T-wave changes, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span> (<a href="#S6">6</a>).  </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Gloucester Pharmaceuticals, Inc. at 1-866-223-7145 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Carefully monitor <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT) and International Normalized Ratio (INR) in patients concurrently administered ISTODAX and Coumadin derivatives (<a href="#S7.1">7.1</a>).</li>
<li>Strong CYP3A4 inhibitors may increase concentrations of ISTODAX and should be avoided (<a href="#S7.2">7.2</a>).</li>
<li>Potent CYP3A4 inducers may decrease concentrations of ISTODAX and should be avoided (<a href="#S7.2">7.2</a>).</li>
</ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 11/2009</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1   Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2   Dose Modification</a></h2>
<h2><a href="#section-2.3" class="toc">2.3   Instructions for Preparation and Intravenous Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1   Monitoring: Laboratory Tests</a></h2>
<h2><a href="#section-5.2" class="toc">5.2   Hematologic</a></h2>
<h2><a href="#section-5.3" class="toc">5.3   Electrocardiographic Changes</a></h2>
<h2><a href="#section-5.4" class="toc">5.4   Use in Pregnancy</a></h2>
<h2><a href="#section-5.5" class="toc">5.5   Use in Women of Childbearing Potential</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1    Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1    Coumadin or Coumadin Derivatives</a></h2>
<h2><a href="#section-7.2" class="toc">7.2   Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes</a></h2>
<h2><a href="#section-7.3" class="toc">7.3   Drugs that Inhibit Drug Transport Systems</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1   Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  Baseline Patient Characteristics</a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Clinical Results</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h2><a href="#section-15.1" class="toc">How Supplied</a></h2>
<h2><a href="#section-15.2" class="toc">Storage</a></h2>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1   Instructions</a></h2>
<h2><a href="#section-16.2" class="toc"></a></h2>
<h2><a href="#section-16.3" class="toc">FDA-Approved Patient Labeling</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">ISTODAX is indicated for treatment of cutaneous T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (CTCL) in patients who have received at least one prior systemic therapy.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1   Dosing Information</h2>
<p class="First">The recommended dose of romidepsin is 14 mg/m<span class="Sup">2</span> administered intravenously over a 4-hour period on days 1, 8 and 15 of a 28-day cycle.  Cycles should be repeated every 28 days provided that the patient continues to benefit from and tolerates the therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2   Dose Modification</h2>
<p class="First"><span class="Italics">Nonhematologic toxicities except <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span></span></p>
<ul class="Disc">
<li>Grade 2 or 3 toxicity: Treatment with romidepsin should be delayed until toxicity returns to <span class="Bold">≤</span>Grade 1 or baseline, then therapy may be restarted at 14 mg/m<span class="Sup">2</span>.  If Grade 3 toxicity recurs, treatment with romidepsin should be delayed until toxicity returns to <span class="Bold">≤</span>Grade 1 or baseline and the dose should be permanently reduced to 10 mg/m<span class="Sup">2</span>.</li>
<li>Grade 4 toxicity: Treatment with romidepsin should be delayed until toxicity returns to ≤Grade 1 or baseline, then the dose should be permanently reduced to 10 mg/m<span class="Sup">2</span>.</li>
<li>Romidepsin should be discontinued if Grade 3 or 4 toxicities recur after dose reduction.</li>
</ul>
<p><span class="Italics">Hematologic toxicities</span></p>
<ul class="Disc">
<li>Grade 3 or 4 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>: Treatment with romidepsin should be delayed until the specific <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> returns to ANC ≥1.5×10<span class="Sup">9</span>/L and/or platelet count ≥75×10<span class="Sup">9</span>/L or baseline, then therapy may be restarted at 14 mg/m<span class="Sup">2</span>.</li>
<li>Grade 4 febrile (≥38.5ºC) <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> that requires platelet transfusion: Treatment with romidepsin should be delayed until the specific <span class="product-label-link" type="condition" conceptid="4179922" conceptname="Cytopenia">cytopenia</span> returns to ≤Grade 1 or baseline, and then the dose should be permanently reduced to 10 mg/m<span class="Sup">2</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3   Instructions for Preparation and Intravenous Administration</h2>
<p class="First">ISTODAX should be handled in a manner consistent with recommended safe procedures for handling cytotoxic drugs.</p>
<p>ISTODAX must be reconstituted with the supplied diluent and further diluted with 0.9% Sodium Chloride Injection, USP before intravenous infusion.</p>
<ul class="Disc">
<li>Each 10 mg single-use vial of ISTODAX (romidepsin) must be reconstituted with 2 mL of the supplied Diluent.  With a suitable syringe, aseptically withdraw 2 mL from the supplied Diluent vial, and slowly inject it into the ISTODAX (romidepsin) for injection vial.  Swirl the contents of the vial until there are no visible particles in the resulting solution.  The reconstituted solution will contain ISTODAX 5 mg/mL.  The reconstituted ISTODAX solution is chemically stable for at least 8 hours at room temperature.</li>
<li>Extract the appropriate amount of ISTODAX from the vials to deliver the desired dose, using proper aseptic technique.  Before intravenous infusion, further dilute ISTODAX in 500 mL 0.9% Sodium Chloride Injection, USP.</li>
<li>Infuse over 4 hours.</li>
</ul>
<p>The diluted solution is compatible with polyvinyl chloride (PVC), ethylene vinyl acetate (EVA), polyethylene (PE) infusion bags as well as glass bottles, and is chemically stable for at least 24 hours when stored at room temperature.  However, it should be administered as soon after dilution as possible.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration before administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">ISTODAX is supplied as a kit which includes a sterile, lyophilized powder in a single-use vial containing 10 mg of romidepsin and 20 mg of the bulking agent, povidone, USP.  In addition, each kit includes 1 sterile vial containing 2 mL (deliverable volume) of the Diluent composed of 80% propylene glycol, USP, and 20% dehydrated alcohol, USP.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1   Monitoring: Laboratory Tests</h2>
<p class="First">Due to the risk of QT prolongation, potassium and magnesium should be within the normal range before administration of ISTODAX <span class="Italics">[See <a href="#S5.3">Warnings and Precautions (5.3)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2   Hematologic</h2>
<p class="First">Treatment with ISTODAX can cause <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>), and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>; therefore, these hematological parameters should be monitored during treatment with ISTODAX, and the dose should be modified, as necessary <span class="Italics">[See <a href="#S2.2">Dosage and Administration (2.2)</a> and <a href="#S6">Adverse Reactions (6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3   Electrocardiographic Changes</h2>
<p class="First">Several treatment-emergent morphological changes in ECGs (including T-wave and ST-segment changes) have been reported in clinical studies.  The clinical significance of these changes is unknown <span class="Italics">[See <a href="#S6">Adverse Reactions (6)</a>].</span></p>
<p>In patients with congenital <span class="product-label-link" type="condition" conceptid="314664" conceptname="Long QT syndrome">long QT syndrome</span>, patients with a history of significant cardiovascular disease, and patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation, appropriate cardiovascular monitoring precautions should be considered, such as the monitoring of electrolytes and ECGs at baseline and periodically during treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4   Use in Pregnancy</h2>
<p class="First">There are no adequate and well-controlled studies of ISTODAX in pregnant women.  However, based on its mechanism of action, ISTODAX may cause fetal harm when administered to a pregnant woman.  A study in rats did not expose pregnant animals to enough romidepsin to fully evaluate adverse outcomes.</p>
<p>If this drug is used during pregnancy, or if the patient becomes pregnant while taking ISTODAX, the patient should be apprised of the potential hazard to the fetus <span class="Italics">[See <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5   Use in Women of Childbearing Potential</h2>
<p class="First">Advise women of childbearing potential that ISTODAX may reduce the effectiveness of estrogen-containing contraceptives.  An<span class="Italics"> in vitro </span>binding assay determined that romidepsin competes with β-estradiol for binding to estrogen receptors <span class="Italics">[See <a href="#S13.1">Nonclinical Toxicology (13.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1    Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The safety of ISTODAX was evaluated in 185 patients with CTCL in 2 single arm clinical studies in which patents received a starting dose of 14 mg/m<span class="Sup">2</span>.  The mean duration of treatment in these studies was 5.6 months (range: &lt;1 to 83.4 months).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Common Adverse Reactions</span></p>
<p>Table 1 summarizes the most frequent adverse reactions (&gt; 20%) regardless of causality using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE, Version 3.0).  Due to methodological differences between the studies, the AE data are presented separately for Study 1 and Study 2.  Adverse reactions are ranked by their incidence in Study 1.  Laboratory abnormalities commonly reported (&gt;20%) as adverse reactions are included in Table 1.</p>
<table width="100%">
<caption><span>Table 1. Adverse Reactions  Occurring in &gt;20% of Patients in Either CTCL Study (N=185)</span></caption>
<col align="left" valign="bottom" width="40%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="15%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2">Adverse Reactions n (%)</th>
<th class="Rrule" align="center" colspan="2">Study 1<br>  (n=102)</th>
<th class="Rrule" align="center" colspan="2">Study 2<br>  (n=83)</th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">All</th>
<th class="Lrule" align="center">Grade 3 or 4</th>
<th class="Lrule" align="center">All</th>
<th class="Lrule Rrule" align="center">Grade 3 or 4</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Italics">Any adverse reaction</span></td>
<td class="Rrule" align="center"><span class="Italics">99 (97)</span></td>
<td class="Rrule" align="center"><span class="Italics">36 (35)</span></td>
<td class="Rrule" align="center"><span class="Italics">83 (100)</span></td>
<td class="Rrule" align="center"><span class="Italics">68 (82)</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">57 (56)</td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">71 (86)</td>
<td class="Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span></td>
<td class="Rrule" align="center">54 (53)</td>
<td class="Rrule" align="center">8 (8)</td>
<td class="Rrule" align="center">64 (77)</td>
<td class="Rrule" align="center">12 (14)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></td>
<td class="Rrule" align="center">47 (46)</td>
<td class="Rrule" align="center">11 (11)</td>
<td class="Rrule" align="center">45 (54)</td>
<td class="Rrule" align="center">27 (33)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="center">35 (34)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">43 (52)</td>
<td class="Rrule" align="center">8 (10)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Rrule" align="center">23 (23)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">45 (54)</td>
<td class="Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></td>
<td class="Rrule" align="center">22 (22)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">23 (28)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">20 (20)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">22 (7)</td>
<td class="Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></td>
<td class="Rrule" align="center">20 (20)</td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">19 (23)</td>
<td class="Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td class="Rrule" align="center">19 (19)</td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">60 (72)</td>
<td class="Rrule" align="center">13 (16)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">17 (17)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">54 (65)</td>
<td class="Rrule" align="center">12 (14)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></td>
<td class="Rrule" align="center">15 (15)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">33 (40)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Rrule" align="center">12 (12)</td>
<td class="Rrule" align="center">2 (2)</td>
<td class="Rrule" align="center">32 (39)</td>
<td class="Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Rrule" align="center">11 (11)</td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">47 (57)</td>
<td class="Rrule" align="center">22 (27)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Rrule" align="center">7 (7)</td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">19 (23)</td>
<td class="Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">7 (7)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">26 (31)</td>
<td class="Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td class="Rrule" align="center">6 (6)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">17 (20)</td>
<td class="Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span>/<span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span></td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">22 (27)</td>
<td class="Rrule" align="center">7 (8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">Hypocalcemia</span></td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">43 (52)</td>
<td class="Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">38 (46)</td>
<td class="Rrule" align="center">18 (22)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">Lymphopenia</span></td>
<td class="Rrule" align="center">4 (4)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">47 (57)</td>
<td class="Rrule" align="center">31 (37)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased</td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">18 (22)</td>
<td class="Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">23 (28)</td>
<td class="Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span></td>
<td class="Rrule" align="center">3 (3)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">40 (48)</td>
<td class="Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Electrocardiogram ST-T wave changes</td>
<td class="Rrule" align="center">2 (2)</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">52 (63)</td>
<td class="Rrule" align="center">0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Rrule" align="center">2 (2)</td>
<td class="Rrule" align="center">2 (2)</td>
<td class="Rrule" align="center">42 (51)</td>
<td class="Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span></td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">1 (&lt;1)</td>
<td class="Rrule" align="center">17 (20)</td>
<td class="Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4284559" conceptname="Hypermagnesemia">Hypermagnesemia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">22 (27)</td>
<td class="Rrule" align="center">7 (8)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4177973" conceptname="Hypophosphatemia">Hypophosphatemia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">22 (27)</td>
<td class="Rrule" align="center">8 (10)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4147761" conceptname="Hyperuricemia">Hyperuricemia</span></td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">0</td>
<td class="Rrule" align="center">27 (33)</td>
<td class="Rrule" align="center">7 (8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Serious Adverse Reactions</span></p>
<p>Serious adverse reactions reported in &gt; 2% of patients in Study 1 were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>.  In Study 2, serious adverse reactions in &gt; 2% of patients were <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, central line <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p>Most <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were due to disease progression.  In Study 1, there were two <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="4259490" conceptname="Cardiorespiratory failure">cardiopulmonary failure</span> and <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>.  In Study 2, there were six <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (4), <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, and <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">acute respiratory distress syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Discontinuations</span></p>
<p>Discontinuation due to an adverse event occurred in 21% of patients in Study 1 and 11% in Study 2.  Discontinuations occurring in at least 2% of patients in either study included <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, QT prolongation, and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1    Coumadin or Coumadin Derivatives</h2>
<p class="First">Prolongation of PT and elevation of INR were observed in a patient receiving ISTODAX concomitantly with warfarin.  Although the interaction potential between ISTODAX and Coumadin or Coumadin derivatives has not been formally studied, physicians should carefully monitor PT and INR in patients concurrently administered ISTODAX and Coumadin or Coumadin derivatives <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2   Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes</h2>
<p class="First">Romidepsin is metabolized by CYP3A4.  Although there are no formal drug interaction studies for ISTODAX, strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) may increase concentrations of romidepsin.  Therefore, co-administration with strong CYP3A4 inhibitors should be avoided if possible.  Caution should be exercised with concomitant use of moderate CYP3A4 inhibitors.</p>
<p>Co-administration of potent CYP3A4 inducers (e.g., dexamethasone, carbamazepine, phenytoin, rifampin, rifabutin, rifapentine, phenobarbital) may decrease concentrations of romidepsin and should be avoided if possible.  Patients should also refrain from taking St. John's Wort.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3   Drugs that Inhibit Drug Transport Systems</h2>
<p class="First">Romidepsin is a substrate of the efflux transporter P-glycoprotein (P-gp, ABCB1).  If ISTODAX is administered with drugs that inhibit P-gp, increased concentrations of romidepsin are likely, and caution should be exercised.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Pregnancy Category D <span class="Italics"> [See <a href="#S5">'Warnings and Precautions' section</a>].</span></p>
<p>There are no adequate and well-controlled studies of ISTODAX in pregnant women.  However, based on its mechanism of action, ISTODAX may cause fetal harm when administered to a pregnant woman.  A study in rats did not expose pregnant animals to enough romidepsin to fully evaluate adverse developmental outcomes.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking ISTODAX, the patient should be apprised of the potential harm to the fetus.</p>
<p>In an animal reproductive study, pregnant rats received daily intravenous romidepsin during the period of organogenesis up to a dose of 0.06 mg/kg/day (0.36 mg/m<span class="Sup">2</span>/day).  This dose in rats is approximately equivalent to 18% the estimated human daily dose based on body surface area and resulted in 5% reduction in fetal weight.  Embryofetal toxicities associated with the use of ISTODAX were not adequately assessed in this study.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether romidepsin is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from ISTODAX, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of ISTODAX in pediatric patients has not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the 167 patients with CTCL in trials, 23% were &gt;65 years old.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects; however, greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6   <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> study for ISTODAX has been conducted.  Mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> does not alter pharmacokinetics of romidepsin based on a population pharmacokinetic analysis.  Patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be treated with caution <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">No dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> study for ISTODAX has been conducted.  Based upon the population pharmacokinetic analysis, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not expected to significantly influence drug exposure.  The effect of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on romidepsin pharmacokinetics has not been studied.  Thus, patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be treated with caution <span class="Italics">[See <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">No specific information is available on the treatment of overdosage of ISTODAX.</p>
<p>Toxicities in a single-dose study in rats or dogs, at intravenous romidepsin doses up to 2.2 fold the recommended human dose based on the body surface area, included irregular respiration, irregular heart beat, <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">staggering gait</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, and <span class="product-label-link" type="condition" conceptid="4198075" conceptname="Tonic seizure">tonic convulsions</span>.</p>
<p>In the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, it is reasonable to employ the usual supportive measures, e.g., clinical monitoring and supportive therapy, if required.  There is no known antidote for ISTODAX and it is not known if ISTODAX is dialyzable.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Romidepsin, a histone deacetylase (HDAC) inhibitor, is a bicyclic depsipeptide.  At room temperature, romidepsin is a white powder and is described chemically as (1<span class="Italics">S</span>,4<span class="Italics">S</span>,7<span class="Italics">Z</span>,10<span class="Italics">S</span>,16<span class="Italics">E</span>,21<span class="Italics">R</span>)-7-ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone.  The empirical formula is C<span class="Sub">24</span>H<span class="Sub">36</span>N<span class="Sub">4</span>O<span class="Sub">6</span>S<span class="Sub">2</span>.</p>
<p>The molecular weight is 540.71 and the structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6005c345-ccf9-4fff-8660-3fd73485b0d9&amp;name=istodax-01.jpg"></div>
<p>ISTODAX (romidepsin) for injection is intended for intravenous infusion only after reconstitution with the supplied Diluent and after further dilution with 0.9% Sodium Chloride, USP.</p>
<p>ISTODAX is supplied as a kit containing two vials.</p>
<p>ISTODAX (romidepsin) for injection is a sterile lyophilized white powder and is supplied in a single-use vial containing 10 mg romidepsin and 20 mg povidone, USP.</p>
<p>Diluent for ISTODAX is a sterile clear solution and is supplied in a single-use vial containing a 2-mL deliverable volume.  Diluent for ISTODAX contains 80% (v/v) propylene glycol, USP and 20% (v/v) dehydrated alcohol, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1   Mechanism of Action</h2>
<p class="First">Romidepsin is a histone deacetylase (HDAC) inhibitor.  HDACs catalyze the removal of acetyl groups from acetylated lysine residues in histones, resulting in the modulation of gene expression.  HDACs also deacetylate non-histone proteins, such as transcription factors.  <span class="Italics">In vitro</span>, romidepsin causes the accumulation of acetylated histones, and induces cell cycle arrest and <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span> of some cancer cell lines with IC<span class="Sub">50</span> values in the nanomolar range.  The mechanism of the antineoplastic effect of romidepsin observed in nonclinical and clinical studies has not been fully characterized.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Absorption</span></p>
<p>Romidepsin exhibited linear pharmacokinetics across doses ranging from 1.0 to 24.9 mg/m<span class="Sup">2</span> when administered intravenously over 4 hours in patients with advanced cancers.</p>
<p>In patients with T cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> who received 14 mg/m<span class="Sup">2</span> of romidepsin intravenously over a 4-hour period on days 1, 8 and 15 of a 28-day cycle, geometric mean values of the maximum plasma concentration (C<span class="Sub">max</span>) and the area under the plasma concentration versus time curve (AUC<span class="Sub">0-inf</span>) were 377 ng/mL and 1549 ng*hr/mL, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.2"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Distribution</span></p>
<p>Romidepsin is highly protein bound in plasma (92% to 94%) over the concentration range of 50 ng/mL to 1000 ng/mL with α1-acid-glycoprotein (AAG) being the principal binding protein.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.3"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Metabolism</span></p>
<p>Romidepsin undergoes extensive metabolism <span class="Italics">in vitro</span> primarily by CYP3A4 with minor contribution from CYP3A5, CYP1A1, CYP2B6, and CYP2C19.  At therapeutic concentrations, romidepsin did not competitively inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 <span class="Italics">in vitro</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.4"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Excretion</span></p>
<p>Following 4-hour intravenous administration of romidepsin at 14 mg/m<span class="Sup">2</span> on days 1, 8 and 15 of a 28-day cycle in patients with T cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span>, the terminal half-life (t<span class="Sub">1/2</span>) was approximately 3 hours.  No accumulation of plasma concentration of romidepsin was observed after repeated dosing.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.5"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Effect of Age, Gender or Race</span></p>
<p>The population pharmacokinetic analysis of romidepsin showed that age, gender, or race (white <span class="Italics">vs</span> black) did not appear to influence the pharmacokinetics of romidepsin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.6"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>No dedicated <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> study has been conducted for ISTODAX.  The population pharmacokinetic analysis indicates that mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [total bilirubin (TB) ≤ upper limit of normal (ULN) and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST) &gt; ULN; or TB &gt; 1.0x - 1.5x ULN and any AST] had no significant influence on romidepsin pharmacokinetics.  As the effect of  moderate (TB &gt; 1.5x - 3x ULN and any AST)  and severe (TB &gt; 3x ULN and any AST) <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of romidepsin is unknown, patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be treated with caution <span class="Italics">[See <a href="#S8.6">Use in Specific Populations (8.6)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.7"></a><p></p>
<h3></h3>
<p class="First"><span class="Italics">Effect of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>No dedicated <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> study has been conducted for ISTODAX.  The population pharmacokinetic analysis showed that romidepsin pharmacokinetics were not affected by mild (estimated creatinine clearance 50 - 80 mL/min), moderate (estimated creatinine clearance 30 - 50 mL/min), or severe (estimated creatinine clearance &lt; 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Nonetheless, the effect of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> on romidepsin pharmacokinetics has not been studied.  Thus, patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be treated with caution <span class="Italics">[See <a href="#S8.7">Use in Specific Populations (8.7)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Carcinogenicity studies have not been performed with romidepsin.  Romidepsin was not mutagenic <span class="Italics">in vitro</span> in the bacterial reverse mutation assay (Ames test) or the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay.  Romidepsin was not clastogenic in an <span class="Italics">in vivo</span> rat bone marrow micronucleus assay when tested to the maximum tolerated dose (MTD) of 1 mg/kg in males and 3 mg/kg in females (6 and 18 mg/m<span class="Sup">2</span> in males and females, respectively).  These doses were up to 1.3-fold the recommended human dose, based on body surface area.</p>
<p>Based on non-clinical findings, male and female fertility may be compromised by treatment with ISTODAX.  In a 26-week toxicology study, romidepsin administration resulted in testicular degeneration in rats at 0.33 mg/kg/dose (2 mg/m<span class="Sup">2</span>/dose) following the clinical dosing schedule.  This dose resulted in AUC<span class="Sub">0-inf.</span> values that were approximately 2% the exposure level in patients receiving the recommended dose of 14 mg/m<span class="Sup">2</span>/dose.  A similar effect was seen in mice after 4 weeks of drug administration at higher doses.  Seminal <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">vesicle</span> and prostate organ weights were decreased in a separate study in rats after 4 weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m<span class="Sup">2</span>/day), approximately 30% the estimated human daily dose based on body surface area.  Romidepsin showed high affinity for binding to estrogen receptors in pharmacology studies.  In a 26-week toxicology study in rats, <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> was seen in the ovary, uterus, vagina and mammary gland of females administered doses as low as 0.1 mg/kg/dose (0.6 mg/m<span class="Sup">2</span>/dose) following the clinical dosing schedule.  This dose resulted in AUC<span class="Sub">0-inf.</span> values that were 0.3% of those in patients receiving the recommended dose of 14 mg/m<span class="Sup">2</span>/dose.  Maturation arrest of ovarian follicles and decreased weight of ovaries were observed in a separate study in rats after four weeks of daily drug administration at 0.1 mg/kg/day (0.6 mg/m<span class="Sup">2</span>/day).  This dose is approximately 30% the estimated human daily dose based on body surface area.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">ISTODAX was evaluated in 2 multicenter, single-arm clinical studies in patients with CTCL.  Overall, 167 patients with CTCL were treated in the US, Europe, and Australia.  Study 1 included 96 patients with confirmed CTCL after failure of at least 1 prior systemic therapy.  Study 2 included 71 patients with a primary diagnosis of CTCL who received at least 2 prior skin directed therapies or one or more systemic therapies.  Patients were treated with ISTODAX at a starting dose of 14 mg/m<span class="Sup">2</span> infused over 4 hours on days 1, 8, and 15 every 28 days.</p>
<p>In both studies, patients could be treated until disease progression at the discretion of the investigator and local regulators.  Objective disease response was evaluated according to a composite endpoint that included assessments of skin involvement, lymph node and visceral involvement, and abnormal circulating T-cells ("Sézary cells.").</p>
<p>The primary efficacy endpoint for both studies was overall objective disease response rate (ORR) based on the investigator assessments, and defined as the proportion of patients with confirmed complete response (CR) or partial response (PR).  CR was defined as no evidence of disease and PR as ≥50% improvement in disease.  Secondary endpoints in both studies included duration of response and time to response.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1  Baseline Patient Characteristics</h2>
<p class="First">Demographic and disease characteristics of the patients in Study 1 and Study 2 are provided in Table 2.</p>
<table width="80%">
<caption><span>Table 2. Baseline Patient Characteristics</span></caption>
<col align="left" valign="middle" width="60%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead><tr class="First Last">
<th align="center">Characteristic</th>
<th align="center">Study 1<br> (N=96)</th>
<th align="center">Study 2<br> (N=71)</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Age </td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  N</td>
<td align="center">96</td>
<td align="center">71</td>
</tr>
<tr>
<td align="left">  Mean (SD)</td>
<td align="center">57 (12)</td>
<td align="center">56 (13)</td>
</tr>
<tr class="Botrule">
<td align="left">  Median (Range)</td>
<td align="center">57 (21, 89)</td>
<td align="center">57 (28, 84)</td>
</tr>
<tr>
<td align="left">Sex, n (%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Men</td>
<td align="center">59 (61)</td>
<td align="center">48 (68)</td>
</tr>
<tr class="Botrule">
<td align="left">  Women</td>
<td align="center">37 (39)</td>
<td align="center">23 (32)</td>
</tr>
<tr>
<td align="left">Race, n (%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  White</td>
<td align="center">90 (94)</td>
<td align="center">55 (77)</td>
</tr>
<tr>
<td align="left">  Black</td>
<td align="center">5 ( 5)</td>
<td align="center">15 (21)</td>
</tr>
<tr class="Botrule">
<td align="left">  Other/Not Reported</td>
<td align="center">1 ( 1)</td>
<td align="center">1 ( 1)</td>
</tr>
<tr>
<td align="left" colspan="2">Stage of Disease at Study Entry, n (%)</td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  IA</td>
<td align="center">0 ( 0)</td>
<td align="center">1 ( 1)</td>
</tr>
<tr>
<td align="left">  IB</td>
<td align="center">15 (16)</td>
<td align="center">6 ( 9)</td>
</tr>
<tr>
<td align="left">  IIA</td>
<td align="center">13 (14)</td>
<td align="center">2 ( 3)</td>
</tr>
<tr>
<td align="left">  IIB</td>
<td align="center">21 (22)</td>
<td align="center">14 (20)</td>
</tr>
<tr>
<td align="left">  III</td>
<td align="center">23 (24)</td>
<td align="center">9 (13)</td>
</tr>
<tr>
<td align="left">  IVA</td>
<td align="center">24 (25)</td>
<td align="center">27 (38)</td>
</tr>
<tr class="Botrule">
<td align="left">  IVB</td>
<td align="center">0 ( 0)</td>
<td align="center">12 (17)</td>
</tr>
<tr>
<td align="left">Number of Prior Skin-Directed Therapies</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td align="left">  Median (Range)</td>
<td align="center">2 (0,6)</td>
<td align="center">1 (0,3)</td>
</tr>
<tr>
<td align="left">Number of Prior Systemic Therapies</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td align="left">  Median (Range)</td>
<td align="center">2 (1, 8)</td>
<td align="center">2 (0, 7)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Clinical Results</h2>
<p class="First">Efficacy outcomes are provided in Table 3.  Median time to first response was 2 months (range 1 to 6) in both studies.  Median time to CR was 6 months in Study 1 and 4 months in Study 2 (range 2 to 9). </p>
<table width="80%">
<caption><span>Table 3. Clinical Results</span></caption>
<col align="left" valign="bottom" width="60%">
<col align="center" valign="bottom" width="20%">
<col align="center" valign="bottom" width="20%">
<thead><tr class="First Last">
<th align="left">Response Rate</th>
<th align="center">Study 1<br> (N=96)</th>
<th align="center">Study 2<br> (N=71)</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>denotes censored value</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left">
<span class="Bold">ORR </span>(CR + PR),  n (%)<br> [95% Confidence Interval]</td>
<td align="center">33 (34)<br> [25, 45]</td>
<td align="center">25 (35)<br> [25, 49]</td>
</tr>
<tr>
<td align="left">  CR, n (%)<br>   [95% Confidence Interval]</td>
<td align="center">6 (6)<br> [2, 13]</td>
<td align="center">4 (6)<br> [2, 14]</td>
</tr>
<tr>
<td align="left">  PR, n (%)<br>   [95% Confidence Interval]</td>
<td align="center">27 (28)<br> [19, 38]</td>
<td align="center">21 (30)<br> [20, 43]</td>
</tr>
<tr>
<td class="Toprule" align="left" colspan="2"><span class="Bold">Duration of Response (months)</span></td>
<td class="Toprule" align="center"></td>
</tr>
<tr>
<td align="left">  N</td>
<td align="center">33</td>
<td align="center">25</td>
</tr>
<tr class="Last">
<td align="left">  Median (range)</td>
<td align="center">15 (1, 20<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>)</td>
<td align="center">11 (1, 66<a href="#footnote-1" class="Sup">*</a>)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="S15"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol>
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: <span class="Italics">Am J Health-Syst Pharm</span>. 2006;63:1172-1193.</li>
<li>Polovich M., White JM, Kelleher LO (eds). Chemotherapy and biotherapy guidelines and recommendations for practice (2<span class="Sup">nd</span> ed.) 2005. Pittsburgh, PA:  Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<h2>How Supplied</h2>
<p class="First">ISTODAX is supplied as a kit including a sterile, lyophilized powder in a single-use vial containing 10 mg of romidepsin and 20 mg of the bulking agent, povidone, USP.  In addition, each kit includes one sterile Diluent vial containing 2 mL (deliverable volume) of 80% propylene glycol, USP, and 20% dehydrated alcohol, USP.</p>
<p><span class="Bold">NDC 46026-983-01:</span>               ISTODAX<span class="Sup">®</span> KIT containing 1 vial of romidepsin, 10 mg and 1 vial of diluent for romidepsin, 2 mL per carton</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.2"></a><p></p>
<h2>Storage</h2>
<p class="First">ISTODAX (romidepsin) for injection is supplied as a kit containing two vials in a single carton.  The carton must be stored at 20° to 25°C, excursions permitted between 15° to 30°C. (See USP Controlled Room Temperature.)</p>
<p>Keep out of reach of children.</p>
<p>Procedures for proper handling and disposal of anticancer drugs should be considered.  Several guidelines on this subject have been published <span class="Italics">[See <a href="#S15">References (15)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#patinfo">FDA-approved patient labeling</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1   Instructions</h2>
<ul class="Disc">
<li>Patients should be instructed to report excessive <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, abnormal heartbeat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> to their physician.  Patients receiving ISTODAX® should seek immediate medical attention if unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs.</li>
<li>ISTODAX binds to estrogen receptors. Advise women of childbearing potential that ISTODAX may reduce the effectiveness of estrogen-containing contraceptives <span class="Italics">[See <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</li>
<li>Patients should be instructed to read the patient insert carefully.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Manufactured for: </span><br>Gloucester Pharmaceuticals, Inc. <br>One Broadway 14<span class="Sup">th</span> Floor  <br>Cambridge MA 02142 USA</p>
<p><span class="Bold">Manufactured by: </span><br>Ben Venue Laboratories, Inc.   <br>300 Northfield Road  <br>Bedford, OH 44146 USA</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="patinfo"></a><a name="section-16.3"></a><p></p>
<h2>FDA-Approved Patient Labeling</h2>
<p class="First">ISTODAX (ISS toe dax) (romidepsin) for injection</p>
<p>Read the patient information that comes with ISTODAX before you receive your first treatment and each time before you are treated.  There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or your treatment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="section-17"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">What is ISTODAX?</span></p>
<p>ISTODAX is a prescription medicine used to treat people with a type of cancer called cutaneous T-cell <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> (CTCL) after at least one other type of medicine by mouth or injection has been tried.  </p>
<p>It is not known if ISTODAX is safe and effective in children under 18 years of age.</p>
<p><span class="Bold">What should I tell my doctor before I receive ISTODAX?</span></p>
<p>Before taking ISTODAX, tell your doctor if you:</p>
<ul class="Disc">
<li>have any heart problems, including an irregular or fast heartbeat, or a condition called QT prolongation.</li>
<li>have kidney problems</li>
<li>have liver problems</li>
<li>have problems with the amount of potassium or magnesium in your blood</li>
<li>have <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>have any other medical conditions</li>
<li>are pregnant or plan to become pregnant.  ISTODAX may harm your unborn baby.  Talk to your doctor about the best way to prevent pregnancy while taking ISTODAX.  <span class="Bold">Tell your doctor right away if you become pregnant while taking ISTODAX.</span>
</li>
<li>are breastfeeding or plan to breastfeed.  It is not known if ISTODAX passes into your breast milk.  You and your doctor should decide if you will take ISTODAX or breast-feed.  Talk to your doctor about the best way to feed your baby while you are being treated with ISTODAX.</li>
</ul>
<p>Tell your doctor about all of the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements.</p>
<p>Some medicines may affect how ISTODAX works, or ISTODAX may affect how your other medicines work.  Especially tell your doctor if you take or use: </p>
<ul class="Disc">
<li>warfarin sodium (Coumadin, Jantoven) or any other blood thinner medicine.  Ask your doctor if you are not sure if you are taking a blood thinner.  Your doctor may want to test your blood more often.</li>
<li>a medicine to treat abnormal heart beats</li>
<li>a type of birth control that contains estrogen, such as birth control pills, patches, implants, or IUDs.  ISTODAX may reduce the effectiveness of estrogen-containing contraceptives.  You may become pregnant.</li>
<li>St. John's Wort (<span class="Italics">Hypericum perforatum</span>)</li>
<li>Dexamethasone (a steroid)</li>
<li>Medicine for:
								<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> (TB)</li>
<li><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>)</li>
<li><span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> (antibiotics)</li>
<li><span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span> (antifungals)</li>
<li>HIV (AIDS)</li>
<li><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
</ul>
</li>
</ul>
<p>Ask your doctor if you are not sure if your medicine is one that is listed above.  Know the medicines you take.  Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ISTODAX?</span></p>
<ul class="Disc">
<li>ISTODAX will be given to you by a healthcare provider as an intravenous (IV) injection into your vein usually over 4 hours.</li>
<li>ISTODAX is usually given on Day 1, Day 8, and Day 15 of a 28 day cycle of treatment.</li>
<li>Your doctor will decide how long you will receive treatment with ISTODAX.</li>
<li>Your doctor will check your blood cell counts and other blood tests regularly during your treatment with ISTODAX to check for side effects of ISTODAX.  Your doctor may decide to do other tests to check your health as needed.</li>
<li>Your doctor may stop your treatment, change when you get your treatment, or change the dose of your treatment if you have certain side effects while taking ISTODAX.</li>
</ul>
<p><span class="Bold">What are the possible side effects of ISTODAX?</span></p>
<p>ISTODAX may cause serious side effects, including:  </p>
<ul class="Disc">
<li>
<span class="Bold">Low blood cell counts: </span>Your doctor will regularly do blood tests to check your blood counts.
								<ul class="Circle">
<li>
<span class="Bold">Low platelets</span>: can cause unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span> under the skin. Talk to your doctor right away if this happens.</li>
<li>
<span class="Bold">Low red blood cells:</span> may make you feel tired and you may get tired easily.  You may look <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>, and feel <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">short of breath</span>.  Tell your doctor if you have these symptoms.</li>
<li>
<span class="Bold">Low white blood cells: </span>can cause you to get <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, which may be serious.</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span> can also happen with normal white blood cells counts.</li>
<li>Tell your doctor right away if you have any of these symptoms: <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, flu-like symptoms, burning on urination, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, or worsening of skin problems.</li>
</ul>
</li>
<li>
<span class="Bold">Changes in the electrical activity of your heart seen on ECG (electrocardiogram)</span>. Your doctor may check your ECG as needed for this problem.  Tell your doctor if your feel an abnormal heart beat, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>.</li>
</ul>
<p>Common side effects of ISTODAX include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and loss of appetite.</li>
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
</ul>
<p>Tell your doctor if you have any side effect that bothers you or does not go away.</p>
<p>These are not all the possible side effects of ISTODAX.  For more information, ask your doctor or pharmacist.</p>
<p>Ask your doctor for medical advice about side effects.  You may report side effects to FDA at 1-800-FDA-1088. </p>
<p><span class="Bold">General information about ISTODAX</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in patient information leaflets.</p>
<p>This patient information leaflet summarizes the most important information about ISTODAX.  If you would like more information, talk with your doctor.  You can ask your pharmacist or doctor for information about ISTODAX that is written for health professionals.  For more information, go to www.ISTODAX.com or call 1-866-223-7145.</p>
<p><span class="Bold">What are the ingredients in ISTODAX?</span></p>
<p>Active ingredient:  romidepsin</p>
<p>Inactive ingredients:  povidone.  The diluent contains 80% propylene glycol and 20% dehydrated alcohol.</p>
<p>Issued <span class="Bold">November 2009</span></p>
<p>Gloucester Pharmaceuticals, Inc. <br>One Broadway, 14th floor; Cambridge, MA 02142</p>
<p>U.S. Patents: 4,977,138; 7,056,884</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - Kit Carton</span></p>
<p>NDC XXXX-XXXX-XX</p>
<p><span class="Bold">ISTODAX<span class="Sup">®</span> Kit</span><br>(romidepsin) <br>for<br>injection</p>
<p><span class="Bold">10 mg<br>per single-use vial</span></p>
<p>Rx Only</p>
<p><span class="Bold">Reconstitution and dilution required.</span></p>
<p>After reconstitution with 2 mL of supplied Diluent,<br>the concentration of ISTODAX<span class="Sup">®</span> is 5 mg/mL.<br>Discard unused portion.</p>
<p>Each kit contains:</p>
<dl>
<dt>–</dt>
<dd>One single-use vial with 10 mg of ISTODAX<span class="Sup">®</span>
</dd>
<dt>–</dt>
<dd>One single-use vial with 2 mL of Diluent</dd>
</dl>
<p>For Intravenous Use Only</p>
<div class="Figure"><img alt="Principal Display Panel - 10 mg Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6005c345-ccf9-4fff-8660-3fd73485b0d9&amp;name=istodax-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ISTODAX 		
					</strong><br><span class="contentTableReg">romidepsin kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:46026-983</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:46026-983-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL, GLASS </td>
<td class="formItem">2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ISTODAX 		
					</strong><br><span class="contentTableReg">romidepsin injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:46026-961</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>romidepsin</strong> (romidepsin) </td>
<td class="formItem">romidepsin</td>
<td class="formItem">10 mg  in 2 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:46026-961-10</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022393</td>
<td class="formItem">01/04/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT FOR ISTODAX 		
					</strong><br><span class="contentTableReg">alcohol and propylene glycol liquid</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:46026-972</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:46026-972-02</td>
<td class="formItem">2 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022393</td>
<td class="formItem">01/04/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022393</td>
<td class="formItem">01/04/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Gloucester Pharmaceuticals, Inc.
							(153288035)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 11/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>966433db-bb0b-475c-afb8-a0996ce4b516</div>
<div>Set id: 6005c345-ccf9-4fff-8660-3fd73485b0d9</div>
<div>Version: 2</div>
<div>Effective Time: 20091118</div>
</div>
</div> <div class="DistributorName">Gloucester Pharmaceuticals, Inc.</div></p>
</body></html>
